



Figure S1 Flow diagram.

Table S1 Baseline characteristics of included patients and excluded patients

Baseline characteristics	Excluded patients (n=992)	Included patients (n=14,174)	P
Demography and clinical features			
Age, median [IQR], y	64 [55–72]	62 [54–70]	0.0005
Female, n (%)	309 (31.15)	4,493 (31.70)	0.719
BMI, kg/m ² , median [IQR]	24.36 [22.58–26.36]	24.49 [22.6–26.57]	0.4984
Current smoking, n (%)	315 (31.75)	4,437 (31.30)	0.7676
Current drinking, n (%)	165 (16.63)	2,300 (16.23)	0.7375
Medical history, n (%)			
Previous stroke	207 (20.87)	3,148 (22.21)	0.3246
Previous TIA	22 (2.22)	394 (2.78)	0.2948
Diabetes	233 (23.49)	3,277 (23.12)	0.7904
Coronary heart disease	92 (9.27)	1,516 (10.70)	0.1598
Atrial fibrillation	76 (7.66)	943 (6.65)	0.2201
Heart failure	8 (0.81)	86 (0.61)	0.4385
Heart valve disease	6 (0.60)	54 (0.38)	0.2776
Hypertension	651 (65.63)	8,843 (62.39)	0.0417
Lipid metabolism disorder	55 (5.54)	1,136 (8.01)	0.0052
Peripheral arterial disease	8 (0.81)	110 (0.78)	0.9161
Infection within 2 weeks before admission	25 (2.52)	425 (3.00)	0.3907
NIHSS score at admission, median [IQR]	3 [2–7]	3 [1–6]	<0.0001
Time from symptom onset to enrollment, median [IQR], h	2 [1–4]	2 [1–4]	0.2923
Therapy, n (%)			
Intravenous thrombolysis	126 (12.70)	1,404 (9.91)	0.0047
Endovascular therapy	7 (0.71)	88 (0.62)	0.7435

IQR, interquartile range; BMI, body mass index; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale.

Table S2 HRs or ORs and 95% CIs of adverse clinical outcomes at 1-year follow-up by leukocyte count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count

Variable	Death					Stroke recurrence					3 ≤ mRS ≤ 6				
	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P
Leukocyte count, n (%)	82 (2.31)	87 (2.46)	116 (3.27)	161 (4.54)		298 (8.39)	297 (8.41)	350 (9.88)	416 (11.72)		376 (10.59)	366 (10.37)	451 (12.73)	659 (18.57)	
Crude HR/OR (95% CI)	Reference	1.06 (0.78–1.44)	1.44 (1.09–1.92)	1.90 (1.45–2.49)	<0.0001	Reference	0.98 (0.83–1.15)	1.17 (1.00–1.37)	1.37 (1.18–1.59)	<0.0001	Reference	0.95 (0.82–1.12)	1.22 (1.05–1.41)	1.83 (1.59–2.11)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.12 (0.83–1.53)	1.46 (1.09–1.95)	1.70 (1.28–2.26)	<0.0001	Reference	1.00 (0.85–1.17)	1.18 (1.01–1.38)	1.36 (1.16–1.58)	<0.0001	Reference	0.98 (0.83–1.16)	1.18 (1.00–1.39)	1.67 (1.42–1.95)	<0.0001
Neutrophil count, n (%)	69 (1.95)	80 (2.26)	111 (3.13)	186 (5.25)		274 (7.72)	301 (8.51)	363 (10.25)	423 (11.93)		308 (8.68)	356 (10.06)	486 (13.72)	702 (19.80)	
Crude HR/OR (95% CI)	Reference	1.16 (0.84–1.60)	1.60 (1.18–2.17)	2.58 (1.95–3.41)	<0.0001	Reference	1.09 (0.93–1.29)	1.29 (1.10–1.51)	1.51 (1.30–1.77)	<0.0001	Reference	1.17 (1.00–1.38)	1.60 (1.37–1.87)	2.47 (2.13–2.86)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.17 (0.84–1.63)	1.48 (1.09–2.02)	2.00 (1.49–2.69)	<0.0001	Reference	1.10 (0.93–1.29)	1.27 (1.08–1.49)	1.45 (1.23–1.69)	<0.0001	Reference	1.11 (0.93–1.33)	1.42 (1.20–1.69)	1.88 (1.59–2.21)	<0.0001
Lymphocyte count, n (%)	179 (5.07)	109 (3.03)	94 (2.69)	64 (1.80)		370 (10.49)	371 (10.33)	311 (8.91)	309 (8.67)		681 (19.30)	456 (12.69)	383 (10.98)	332 (9.32)	
Crude HR/OR (95% CI)	Reference	0.63 (0.50–0.80)	0.57 (0.44–0.74)	0.38 (0.28–0.50)	<0.0001	Reference	1.03 (0.89–1.19)	0.86 (0.74–1.01)	0.87 (0.75–1.02)	0.0181	Reference	0.63 (0.55–0.71)	0.54 (0.47–0.63)	0.46 (0.40–0.53)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.90 (0.70–1.16)	0.97 (0.74–1.27)	0.70 (0.51–0.95)	0.0564	Reference	1.09 (0.94–1.27)	0.95 (0.81–1.11)	0.97 (0.83–1.14)	0.412	Reference	0.79 (0.68–0.92)	0.81 (0.69–0.95)	0.75 (0.64–0.89)	<0.0001
Monocyte count, n (%)	87 (2.49)	94 (2.64)	99 (2.74)	166 (4.72)		347 (9.93)	311 (8.75)	330 (9.14)	373 (10.61)		377 (10.79)	408 (11.48)	446 (12.35)	621 (17.66)	
Crude HR/OR (95% CI)	Reference	1.04 (0.77–1.40)	1.08 (0.80–1.46)	1.77 (1.34–2.33)	<0.0001	Reference	0.89 (0.76–1.05)	0.95 (0.81–1.11)	1.12 (0.95–1.31)	0.1165	Reference	1.03 (0.88–1.20)	1.05 (0.90–1.23)	1.50 (1.29–1.74)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.00 (0.74–1.35)	1.05 (0.77–1.42)	1.42 (1.07–1.89)	0.0086	Reference	0.90 (0.77–1.06)	0.95 (0.81–1.11)	1.10 (0.93–1.29)	0.2051	Reference	1.06 (0.89–1.25)	1.06 (0.89–1.25)	1.41 (1.19–1.66)	<0.0001
Eosinophil count, n (%)	155 (4.75)	92 (2.61)	105 (2.64)	94 (2.76)		375 (11.49)	314 (8.91)	379 (9.53)	293 (8.60)		608 (18.63)	390 (11.07)	453 (11.39)	401 (11.77)	
Crude HR/OR (95% CI)	Reference	0.58 (0.44–0.75)	0.58 (0.45–0.75)	0.61 (0.47–0.79)	<0.0001	Reference	0.80 (0.68–0.93)	0.84 (0.73–0.97)	0.76 (0.65–0.89)	0.0021	Reference	0.55 (0.48–0.63)	0.56 (0.49–0.64)	0.58 (0.50–0.67)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.80 (0.61–1.06)	0.82 (0.63–1.07)	0.89 (0.68–1.18)	0.387	Reference	0.83 (0.71–0.97)	0.90 (0.77–1.04)	0.82 (0.70–0.96)	0.0422	Reference	0.70 (0.60–0.82)	0.77 (0.66–0.90)	0.81 (0.69–0.96)	0.0144
Basophil count, n (%)	60 (3.15)	228 (3.39)	62 (2.71)	96 (2.94)		171 (8.98)	681 (10.14)	209 (9.15)	300 (9.19)		255 (13.39)	918 (13.66)	265 (11.60)	414 (12.68)	
Crude HR/OR (95% CI)	Reference	1.06 (0.74–1.50)	0.77 (0.51–1.17)	0.85 (0.58–1.25)	0.0762	Reference	1.21 (0.98–1.48)	1.08 (0.85–1.38)	1.13 (0.91–1.41)	0.9409	Reference	1.10 (0.91–1.33)	0.86 (0.69–1.07)	0.93 (0.76–1.14)	0.1003
Adjusted HR/OR (95% CI)	Reference	1.10 (0.77–1.56)	0.91 (0.59–1.38)	1.07 (0.73–1.57)	0.8623	Reference	1.18 (0.96–1.45)	1.10 (0.86–1.39)	1.15 (0.92–1.44)	0.6591	Reference	1.16 (0.94–1.43)	1.03 (0.81–1.32)	1.21 (0.96–1.51)	0.5955

mRS, modified Rankin Scale; HR, hazard ratio; OR, odds ratio; CI, confidence interval.

Table S3 HRs or ORs and 95% CIs of adverse clinical outcomes at 3-month follow-up by leukocyte count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count

Variable	Death					Stroke recurrence					3 ≤ mRS ≤ 6				
	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P
Leukocyte count, n (%)	28 (0.79)	34 (0.96)	46 (1.30)	96 (2.70)		187 (5.26)	180 (5.10)	215 (6.07)	290 (8.17)		360 (10.14)	376 (10.65)	474 (13.38)	705 (19.86)	
Crude HR/OR (95% CI)	Reference	1.20 (0.73–1.99)	1.68 (1.05–2.70)	3.17 (2.07–4.87)	<0.0001	Reference	0.95 (0.77–1.17)	1.14 (0.93–1.39)	1.54 (1.28–1.86)	<0.0001	Reference	1.03 (0.88–1.20)	1.36 (1.17–1.59)	2.15 (1.86–2.48)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.33 (0.80–2.22)	1.75 (1.08–2.85)	2.79 (1.78–4.39)	<0.0001	Reference	0.97 (0.79–1.19)	1.13 (0.93–1.39)	1.48 (1.22–1.80)	<0.0001	Reference	1.04 (0.88–1.23)	1.29 (1.09–1.52)	1.85 (1.57–2.17)	<0.0001
Neutrophil count, n (%)	21 (0.59)	27 (0.76)	44 (1.24)	112 (3.16)		164 (4.62)	188 (5.31)	220 (6.21)	300 (8.46)		300 (8.46)	341 (9.64)	507 (14.31)	767 (21.63)	
Crude HR/OR (95% CI)	Reference	1.32 (0.74–2.34)	2.04 (1.21–3.45)	4.91 (3.06–7.87)	<0.0001	Reference	1.14 (0.92–1.41)	1.30 (1.06–1.60)	1.81 (1.49–2.19)	<0.0001	Reference	1.15 (0.97–1.35)	1.74 (1.49–2.04)	2.90 (2.50–3.37)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.36 (0.76–2.42)	1.94 (1.14–3.31)	3.72 (2.26–6.10)	<0.0001	Reference	1.14 (0.92–1.40)	1.27 (1.04–1.56)	1.67 (1.37–2.04)	<0.0001	Reference	1.06 (0.88–1.26)	1.52 (1.28–1.80)	2.12 (1.79–2.50)	<0.0001
Lymphocyte count, n (%)	86 (2.44)	51 (1.42)	40 (1.15)	27 (0.76)		244 (6.92)	248 (6.90)	195 (5.59)	185 (5.19)		709 (20.10)	479 (13.33)	407 (11.67)	320 (8.98)	
Crude HR/OR (95% CI)	Reference	0.63 (0.44–0.89)	0.52 (0.36–0.77)	0.36 (0.23–0.56)	<0.0001	Reference	1.03 (0.86–1.23)	0.82 (0.68–0.99)	0.79 (0.65–0.96)	0.0027	Reference	0.63 (0.55–0.71)	0.55 (0.48–0.63)	0.43 (0.37–0.49)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.04 (0.71–1.52)	1.08 (0.72–1.63)	0.81 (0.51–1.29)	0.5481	Reference	1.09 (0.91–1.30)	0.90 (0.74–1.09)	0.87 (0.71–1.07)	0.0674	Reference	0.77 (0.66–0.89)	0.76 (0.65–0.89)	0.63 (0.53–0.75)	<0.0001
Monocyte count, n (%)	36 (1.03)	41 (1.15)	46 (1.27)	81 (2.30)		222 (6.36)	198 (5.57)	215 (5.95)	237 (6.74)		407 (11.65)	438 (12.32)	445 (12.32)	625 (17.78)	
Crude HR/OR (95% CI)	Reference	1.05 (0.67–1.66)	1.15 (0.73–1.81)	1.91 (1.25–2.90)	0.001	Reference	0.90 (0.74–1.09)	0.98 (0.80–1.19)	1.12 (0.92–1.36)	0.1833	Reference	1.02 (0.88–1.19)	1.00 (0.86–1.16)	1.47 (1.27–1.71)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.95 (0.59–1.51)	1.22 (0.77–1.93)	1.44 (0.93–2.24)	0.043	Reference	0.91 (0.75–1.11)	0.99 (0.81–1.20)	1.10 (0.90–1.34)	0.2606	Reference	1.04 (0.88–1.23)	1.01 (0.85–1.19)	1.38 (1.17–1.63)	<0.0001
Eosinophil count, n (%)	88 (2.70)	36 (1.02)	43 (1.08)	37 (1.09)		249 (7.63)	198 (5.62)	236 (5.93)	189 (5.55)		652 (19.98)	409 (11.61)	467 (11.74)	387 (11.36)	
Crude HR/OR (95% CI)	Reference	0.41 (0.27–0.60)	0.43 (0.30–0.63)	0.43 (0.29–0.63)	<0.0001	Reference	0.74 (0.61–0.89)	0.79 (0.65–0.94)	0.72 (0.60–0.88)	0.0031	Reference	0.53 (0.46–0.61)	0.53 (0.46–0.61)	0.51 (0.44–0.59)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.64 (0.42–0.97)	0.73 (0.49–1.09)	0.69 (0.46–1.06)	0.0879	Reference	0.78 (0.65–0.95)	0.86 (0.71–1.04)	0.80 (0.66–0.98)	0.0688	Reference	0.69 (0.59–0.81)	0.74 (0.63–0.86)	0.72 (0.61–0.84)	<0.0001
Basophil count, n (%)	21 (1.10)	109 (1.62)	33 (1.44)	41 (1.26)		99 (5.20)	442 (6.58)	132 (5.78)	199 (6.09)		279 (14.65)	947 (14.09)	275 (12.04)	414 (12.68)	
Crude HR/OR (95% CI)	Reference	1.23 (0.70–2.15)	0.92 (0.49–1.75)	0.83 (0.46–1.52)	0.0775	Reference	1.22 (0.94–1.58)	1.06 (0.78–1.44)	1.16 (0.88–1.54)	0.9639	Reference	0.97 (0.81–1.17)	0.76 (0.61–0.94)	0.79 (0.65–0.97)	0.0063
Adjusted HR/OR (95% CI)	Reference	1.22 (0.69–2.16)	1.12 (0.59–2.14)	0.98 (0.53–1.83)	0.4881	Reference	1.20 (0.92–1.55)	1.08 (0.80–1.47)	1.20 (0.91–1.60)	0.5488	Reference	1.01 (0.82–1.24)	0.90 (0.70–1.14)	0.99 (0.79–1.23)	0.5839

mRS, modified Rankin Scale; HR, hazard ratio; OR, odds ratio; CI, confidence interval.

Table S4 HRs or ORs and 95% CIs of adverse clinical outcomes at 1-year follow-up by leukocyte count, neutrophil percent, lymphocyte percent, monocyte percent, eosinophil percent, basophil percent

Variable	Death					Stroke recurrence					3 ≤ mRS ≤ 6				
	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P
Leukocyte count, n (%)	82 (2.31)	87 (2.46)	116 (3.27)	161 (4.54)		298 (8.39)	297 (8.41)	350 (9.88)	416 (11.72)		376 (10.59)	366 (10.37)	451 (12.73)	659 (18.57)	
Crude HR/OR (95% CI)	Reference	1.06 (0.78–1.44)	1.44 (1.09–1.92)	1.90 (1.45–2.49)	<0.0001	Reference	0.98 (0.83–1.15)	1.17 (1.00–1.37)	1.37 (1.18–1.59)	<0.0001	Reference	0.95 (0.82–1.12)	1.22 (1.05–1.41)	1.83 (1.59–2.11)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.12 (0.83–1.53)	1.46 (1.09–1.95)	1.70 (1.28–2.26)	<0.0001	Reference	1.00 (0.85–1.17)	1.18 (1.01–1.38)	1.36 (1.16–1.58)	<0.0001	Reference	0.98 (0.83–1.16)	1.18 (1.00–1.39)	1.67 (1.42–1.95)	<0.0001
Neutrophil percent, n (%)	54 (1.52)	76 (2.14)	113 (3.19)	203 (5.73)		279 (7.87)	294 (8.30)	348 (9.82)	440 (12.42)		272 (7.68)	352 (9.93)	475 (13.40)	753 (21.25)	
Crude HR/OR (95% CI)	Reference	1.32 (0.93–1.88)	2.02 (1.46–2.80)	3.59 (2.64–4.87)	<0.0001	Reference	0.99 (0.84–1.17)	1.19 (1.01–1.40)	1.49 (1.28–1.74)	<0.0001	Reference	1.28 (1.08–1.51)	1.82 (1.55–2.14)	3.10 (2.66–3.61)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.24 (0.87–1.77)	1.70 (1.22–2.37)	2.09 (1.52–2.88)	<0.0001	Reference	0.99 (0.84–1.17)	1.15 (0.97–1.35)	1.36 (1.16–1.59)	<0.0001	Reference	1.19 (0.99–1.42)	1.47 (1.24–1.75)	1.86 (1.57–2.21)	<0.0001
Lymphocyte percent, n (%)	222 (6.27)	96 (2.71)	76 (2.14)	52 (1.47)		440 (12.42)	340 (9.59)	291 (8.21)	290 (8.19)		800 (22.58)	450 (12.70)	341 (9.62)	261 (7.37)	
Crude HR/OR (95% CI)	Reference	0.43 (0.34–0.55)	0.36 (0.27–0.46)	0.25 (0.18–0.34)	<0.0001	Reference	0.77 (0.67–0.89)	0.66 (0.57–0.77)	0.69 (0.59–0.80)	<0.0001	Reference	0.52 (0.46–0.60)	0.39 (0.33–0.44)	0.30 (0.26–0.36)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.63 (0.49–0.81)	0.58 (0.44–0.76)	0.44 (0.32–0.61)	<0.0001	Reference	0.82 (0.71–0.95)	0.73 (0.63–0.86)	0.76 (0.65–0.90)	<0.0001	Reference	0.70 (0.60–0.80)	0.59 (0.50–0.69)	0.51 (0.43–0.60)	<0.0001
Monocyte percent, n (%)	110 (3.10)	115 (3.24)	101 (2.85)	120 (3.39)		379 (10.70)	343 (9.68)	339 (9.57)	300 (8.47)		457 (12.90)	449 (12.67)	440 (12.42)	506 (14.28)	
Crude HR/OR (95% CI)	Reference	0.98 (0.75–1.28)	0.84 (0.63–1.11)	0.93 (0.70–1.22)	0.4095	Reference	0.92 (0.79–1.07)	0.93 (0.79–1.08)	0.81 (0.69–0.96)	0.0215	Reference	0.90 (0.78–1.04)	0.85 (0.73–0.99)	0.91 (0.79–1.06)	0.1248
Adjusted HR/OR (95% CI)	Reference	0.96 (0.73–1.26)	0.81 (0.61–1.08)	0.81 (0.61–1.08)	0.0919	Reference	0.91 (0.78–1.06)	0.93 (0.80–1.09)	0.80 (0.68–0.95)	0.0204	Reference	0.95 (0.80–1.11)	0.91 (0.77–1.08)	0.93 (0.78–1.10)	0.3154
Eosinophil percent, n (%)	177 (5.00)	93 (2.62)	84 (2.38)	92 (2.59)		412 (11.63)	339 (9.55)	315 (8.91)	295 (8.32)		671 (18.94)	414 (11.66)	386 (10.92)	381 (10.74)	
Crude HR/OR (95% CI)	Reference	0.54 (0.42–0.70)	0.50 (0.38–0.65)	0.54 (0.42–0.70)	<0.0001	Reference	0.83 (0.72–0.96)	0.76 (0.65–0.88)	0.72 (0.62–0.84)	<0.0001	Reference	0.57 (0.50–0.66)	0.53 (0.46–0.61)	0.52 (0.45–0.60)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.77 (0.59–1.00)	0.69 (0.52–0.91)	0.75 (0.57–0.99)	0.018	Reference	0.87 (0.75–1.01)	0.80 (0.69–0.94)	0.77 (0.66–0.90)	<0.0001	Reference	0.76 (0.65–0.88)	0.72 (0.61–0.84)	0.72 (0.61–0.84)	<0.0001
Basophil percent, n (%)	138 (3.90)	122 (3.45)	100 (2.82)	86 (2.43)		355 (10.02)	371 (10.49)	328 (9.24)	307 (8.66)		551 (15.56)	496 (14.02)	415 (11.69)	390 (11.01)	
Crude HR/OR (95% CI)	Reference	0.79 (0.61–1.03)	0.60 (0.45–0.80)	0.52 (0.39–0.70)	<0.0001	Reference	1.03 (0.88–1.21)	0.91 (0.77–1.07)	0.89 (0.75–1.05)	0.068	Reference	0.85 (0.74–0.98)	0.65 (0.56–0.76)	0.60 (0.51–0.70)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.88 (0.68–1.16)	0.73 (0.55–0.98)	0.73 (0.54–0.99)	0.022	Reference	1.03 (0.88–1.21)	0.94 (0.79–1.11)	0.93 (0.79–1.11)	0.2639	Reference	0.96 (0.81–1.13)	0.81 (0.68–0.97)	0.83 (0.70–0.99)	0.008

mRS, modified Rankin Scale; HR, hazard ratio; OR, odds ratio; CI, confidence interval.

Table S5 HRs or ORs and 95% CIs of adverse clinical outcomes at 3-month follow-up by leukocyte count, neutrophil percent, lymphocyte percent, monocyte percent, eosinophil percent, basophil percent

Variable	Death					Stroke recurrence					3≤ mRS ≤6				
	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P	Q1	Q2	Q3	Q4	P
Leukocyte count, n (%)	28 (0.79)	34 (0.96)	46 (1.30)	96 (2.70)		187 (5.26)	180 (5.10)	215 (6.07)	290 (8.17)		360 (10.14)	376 (10.65)	474 (13.38)	705 (19.86)	
Crude HR/OR (95% CI)	Reference	1.20 (0.73–1.99)	1.68 (1.05–2.70)	3.17 (2.07–4.87)	<0.0001	Reference	0.95 (0.77–1.17)	1.14 (0.93–1.39)	1.54 (1.28–1.86)	<0.0001	Reference	1.03 (0.88–1.20)	1.36 (1.17–1.59)	2.15 (1.86–2.48)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.33 (0.80–2.22)	1.75 (1.08–2.85)	2.79 (1.78–4.39)	<0.0001	Reference	0.97 (0.79–1.19)	1.13 (0.93–1.39)	1.48 (1.22–1.80)	<0.0001	Reference	1.04 (0.88–1.23)	1.29 (1.09–1.52)	1.85 (1.57–2.17)	<0.0001
Neutrophil percent, n (%)	17 (0.48)	30 (0.85)	41 (1.16)	116 (3.27)		179 (5.05)	165 (4.66)	216 (6.09)	312 (8.81)		248 (7.00)	357 (10.07)	493 (13.91)	817 (23.06)	
Crude HR/OR (95% CI)	Reference	1.60 (0.88–2.91)	2.21 (1.25–3.91)	5.96 (3.56–9.97)	<0.0001	Reference	0.89 (0.72–1.10)	1.15 (0.94–1.41)	1.68 (1.39–2.03)	<0.0001	Reference	1.43 (1.21–1.70)	2.09 (1.77–2.46)	3.81 (3.26–4.46)	<0.0001
Adjusted HR/OR (95% CI)	Reference	1.53 (0.83–2.80)	1.81 (1.02–3.22)	3.22 (1.88–5.51)	<0.0001	Reference	0.88 (0.71–1.09)	1.10 (0.90–1.35)	1.50 (1.23–1.82)	<0.0001	Reference	1.34 (1.11–1.62)	1.69 (1.42–2.02)	2.36 (1.99–2.81)	<0.0001
Lymphocyte percent, n (%)	118 (3.33)	38 (1.07)	32 (0.90)	16 (0.45)		316 (8.92)	204 (5.76)	171 (4.83)	181 (5.11)		840 (23.71)	486 (13.71)	348 (9.82)	241 (6.80)	
Crude HR/OR (95% CI)	Reference	0.34 (0.23–0.49)	0.31 (0.21–0.47)	0.16 (0.10–0.28)	<0.0001	Reference	0.64 (0.53–0.76)	0.54 (0.45–0.66)	0.59 (0.49–0.72)	<0.0001	Reference	0.54 (0.48–0.62)	0.37 (0.32–0.42)	0.26 (0.22–0.31)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.53 (0.36–0.78)	0.57 (0.38–0.87)	0.31 (0.18–0.54)	<0.0001	Reference	0.68 (0.57–0.82)	0.61 (0.50–0.74)	0.66 (0.54–0.80)	<0.0001	Reference	0.72 (0.63–0.84)	0.55 (0.47–0.65)	0.41 (0.35–0.49)	<0.0001
Monocyte percent, n (%)	57 (1.61)	52 (1.47)	51 (1.44)	44 (1.24)		248 (7.00)	229 (6.46)	217 (6.12)	178 (5.02)		527 (14.87)	463 (13.06)	453 (12.79)	472 (13.32)	
Crude HR/OR (95% CI)	Reference	0.81 (0.55–1.20)	0.77 (0.52–1.13)	0.60 (0.40–0.92)	0.0193	Reference	0.94 (0.78–1.14)	0.91 (0.75–1.10)	0.73 (0.59–0.90)	0.0037	Reference	0.79 (0.68–0.91)	0.76 (0.65–0.87)	0.74 (0.63–0.85)	0.0542
Adjusted HR/OR (95% CI)	Reference	0.84 (0.56–1.25)	0.81 (0.54–1.22)	0.56 (0.36–0.87)	0.0124	Reference	0.96 (0.80–1.16)	0.94 (0.77–1.14)	0.75 (0.60–0.92)	0.01	Reference	0.82 (0.70–0.96)	0.83 (0.71–0.98)	0.77 (0.65–0.91)	0.0869
Eosinophil percent, n (%)	98 (2.77)	37 (1.04)	32 (0.91)	37 (1.04)		283 (7.99)	205 (5.77)	192 (5.43)	192 (5.41)		719 (20.29)	450 (12.68)	387 (10.95)	359 (10.12)	
Crude HR/OR (95% CI)	Reference	0.40 (0.27–0.59)	0.35 (0.24–0.53)	0.40 (0.27–0.59)	<0.0001	Reference	0.73 (0.61–0.88)	0.67 (0.55–0.80)	0.68 (0.56–0.81)	<0.0001	Reference	0.59 (0.51–0.67)	0.49 (0.42–0.56)	0.45 (0.39–0.52)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.65 (0.43–0.98)	0.55 (0.36–0.84)	0.64 (0.42–0.96)	0.0089	Reference	0.78 (0.65–0.94)	0.72 (0.60–0.88)	0.75 (0.61–0.91)	0.0017	Reference	0.79 (0.68–0.92)	0.66 (0.56–0.77)	0.63 (0.54–0.74)	<0.0001
Basophil percent, n (%)	67 (1.89)	61 (1.72)	42 (1.18)	34 (0.96)		230 (6.49)	230 (6.50)	214 (6.03)	198 (5.59)		604 (17.05)	501 (14.16)	417 (11.74)	393 (11.09)	
Crude HR/OR (95% CI)	Reference	0.68 (0.47–0.98)	0.41 (0.27–0.62)	0.34 (0.22–0.53)	<0.0001	Reference	0.92 (0.75–1.12)	0.85 (0.69–1.05)	0.81 (0.65–1.00)	0.038	Reference	0.73 (0.63–0.84)	0.55 (0.47–0.64)	0.51 (0.44–0.60)	<0.0001
Adjusted HR/OR (95% CI)	Reference	0.78 (0.53–1.14)	0.55 (0.36–0.85)	0.50 (0.32–0.80)	0.0011	Reference	0.93 (0.76–1.13)	0.89 (0.73–1.10)	0.88 (0.71–1.09)	0.2248	Reference	0.81 (0.69–0.95)	0.68 (0.58–0.81)	0.70 (0.59–0.84)	<0.0001

mRS, modified Rankin Scale; HR, hazard ratio; OR, odds ratio; CI, confidence interval.

Table S6 Reclassification and discrimination statistics for adverse clinical outcomes at 1-year follow-up by leukocyte count, neutrophil percent, lymphocyte percent, monocyte percent, eosinophil percent, basophil percent

Model	C statistic		IDI		NRI (continuous)		NRI (categorical)*	
	Estimate (95% CI)	P value	Estimate (95% CI), %	P value	Estimate (95% CI), %	P value	Estimate (95% CI), %	P value
Death								
Conventional model [†]	0.804 (0.783–0.826)		Reference		Reference		Reference	
Conventional model + leukocyte count	0.809 (0.788–0.831)	0.067	0.008 (0.004–0.012)	<0.001	0.203 (0.109–0.298)	<0.001	0.024 (–0.005–0.053)	0.102
Conventional model + neutrophil percent	0.810 (0.789–0.831)	0.056	0.006 (0.004–0.009)	<0.001	0.292 (0.199–0.385)	<0.001	0.029 (0.0003–0.058)	0.049
Conventional model + lymphocyte percent	0.811 (0.789–0.831)	0.042	0.008 (0.005–0.011)	<0.001	0.311 (0.218–0.403)	<0.001	0.028 (–0.002–0.059)	0.070
Conventional model + monocyte percent	0.804 (0.783–0.826)	0.734	0.0002 (–0.0002–0.0006)	0.233	0.014 (–0.080–0.208)	0.767	0.002 (–0.006–0.010)	0.604
Conventional model + eosinophil percent	0.805 (0.783–0.826)	0.664	0.001 (0.0002–0.002)	0.018	0.123 (0.034–0.213)	0.010	–0.0004 (–0.013–0.012)	0.954
Conventional model + basophil percent	0.804 (0.783–0.826)	0.762	0.001 (–0.001–0.003)	0.325	–0.007 (–0.096–0.083)	0.888	–0.002 (–0.012–0.007)	0.625
Stroke recurrence								
Conventional model [†]	0.601 (0.585–0.617)		Reference		Reference		Reference	
Conventional model + leukocyte count	0.610 (0.594–0.626)	0.004	0.002 (0.0008–0.002)	<0.001	0.142 (0.086–0.198)	<0.001	0.003 (–0.013–0.020)	0.674
Conventional model + neutrophil percent	0.614 (0.598–0.630)	<0.001	0.002 (0.001–0.003)	<0.001	0.134 (0.079–0.190)	<0.001	0.001 (–0.018–0.020)	0.879
Conventional model + lymphocyte percent	0.613 (0.597–0.628)	<0.001	0.002 (0.001–0.002)	<0.001	0.114 (0.058–0.170)	<0.001	0.001 (–0.016–0.019)	0.884
Conventional model + monocyte percent	0.606 (0.590–0.622)	0.082	0.001 (0.0005–0.002)	<0.001	0.085 (0.030–0.141)	0.003	–0.011 (–0.026–0.004)	0.163
Conventional model + eosinophil percent	0.604 (0.588–0.620)	0.039	0.0002 (–0.0001–0.0005)	0.127	0.057 (0.003–0.110)	0.047	0.008 (–0.002–0.002)	0.137
Conventional model + basophil percent	0.601 (0.585–0.617)	0.324	0.0007 (–0.0001–0.0003)	0.505	–0.057 (–0.111–0.004)	0.044	–0.004 (–0.009–0.003)	0.069
3 ≤ mRS ≤ 6								
Conventional model [†]	0.798 (0.787–0.809)		Reference		Reference		Reference	
Conventional model + leukocyte count	0.802 (0.791–0.813)	<0.001	0.006 (0.004–0.008)	<0.001	0.210 (0.162–0.259)	<0.001	0.017 (0.003–0.031)	0.018
Conventional model + neutrophil percent	0.804 (0.793–0.815)	<0.001	0.007 (0.005–0.010)	<0.001	0.256 (0.208–0.305)	<0.001	0.026 (0.010–0.041)	0.002
Conventional model + lymphocyte percent	0.805 (0.794–0.816)	<0.001	0.009 (0.007–0.012)	<0.001	0.276 (0.228–0.324)	<0.001	0.025 (0.008–0.042)	0.004
Conventional model + monocyte percent	0.798 (0.787–0.809)	0.253	0 (0–0)	0.749	0.004 (–0.045–0.053)	0.875	0.0009 (–0.0008–0.003)	0.298
Conventional model + eosinophil percent	0.798 (0.787–0.809)	0.376	0.0005 (–0.0001–0.001)	0.079	0.088 (0.041–0.134)	<0.001	0.002 (–0.004–0.009)	0.485
Conventional model + basophil percent	0.798 (0.787–0.809)	0.566	0.0004 (–0.0002–0.0003)	0.693	–0.038 (–0.086–0.009)	0.122	0.002 (–0.0007–0.005)	0.134

*, Patients were divided into four risk categories by leukocyte count, neutrophil percent, lymphocyte percent, monocyte percent, eosinophil percent, basophil percent. [†], Conventional model: age, sex, BMI, smoking, drinking, hypertension, previous stroke, lipid metabolism disorders, diabetes, atrial fibrillation, coronary heart disease, peripheral arterial disease, heart failure, heart valve disease, NIHSS at admission, time from symptom onset to enrollment, intravenous thrombolysis, endovascular therapy, antiplatelet agents, anticoagulant drugs, lipid-lowering drugs, hypoglycemic treatment, antihypertensive treatment. IDI, integrated discrimination improvement; NRI, net reclassification index; CI, confidence interval; mRS, modified Rankin Scale; BMI, body mass index; NIHSS, National Institutes of Health Stroke Scale.